About Divis Laboratories Ltd
Divis Laboratories Ltd. was established in 1990. The company is a prominent player in the pharmaceuticals and drugs sector. Its headquarters is in Hyderabad, India. The company has decades of experience in manufacturing Active Pharmaceutical Ingredients (APIs). It also has expertise in Nutraceutical Ingredients. They even provide Custom Synthesis of APIs for major pharmaceutical companies.
The company is renowned for its extensive range of products. This includes generic APIs such as Naproxen and Dextromethorphan. It also includes Gabapentin, Pregabalin, and Valsartan. The product list also includes Levetiracetam and Phenylephrine. Additionally, Divis Laboratories produces nutraceutical ingredients like beta-carotene and Lutein. It also produces Astaxanthin and Lycopene. The company also produces Vitamin D3 and Vitamin A. These products highlight the company’s duty to quality and innovation.
Divis Laboratories Ltd. is led by its founder and Managing Director, Dr Murali K. Divi, and the Whole-time Director, Mr Kiran S. Divi. The promoters hold a significant shareholding of approximately 51.90%. This reflects their strong commitment to the company’s growth and success.
Here are the top managing promoters of the company:
The registered office of Divis Laboratories Ltd. is located at 10 & 13 - A, S V Road, Mumbai, Maharashtra 400102. The company’s management team continues to drive its vision. They deliver high-quality pharmaceutical products to meet global healthcare needs.
The company is one of the leading manufacturers of generic APIs globally. Divis Laboratories Ltd. has established itself as a major player in the pharmaceutical industry. It has large-scale manufacturing capabilities. It also adheres to global regulatory standards, which have earned it a reputable position in the market.
The company’s first manufacturing facility was set up in 1995 at Choutuppal, Telangana. This facility marked the beginning of Divis’ journey in large-scale manufacturing. The company received ISO-9002 certification from SGS-Yarsley of the UK in 1997. This certification highlights its commitment to quality standards. By 1999, Divis Laboratories had earned a Certificate of Suitability (CoS) from the European Directorate. This certification was for the quality of its Naproxen production.
In 2002, Divis Laboratories expanded its manufacturing capabilities. They established a second facility at Chippada near Visakhapatnam. This expansion was crucial for meeting the growing global demand for APIs and intermediates. The company went public with its initial public offering (IPO) on February 17, 2003. The IPO further solidified its financial foundation and enabled future growth.
Significant milestones marked the early 2000s for Divis Laboratories. The company received multiple certifications, including ISO-14001, from SGS International AG of Switzerland. It also received OHSAS-18001 from BVQI of London. These reflect its adherence to international standards in quality and occupational health and safety. The US FDA also inspected and approved the company’s facilities. This approval underlines its compliance with stringent regulatory requirements.
In 2010, Divis Laboratories Ltd. established a research centre in Hyderabad. It was to focus on fundamental research in niche business segments. This move aimed to enhance the company’s R&D capabilities and foster innovation. Over the years, Divis Laboratories has continued to expand its product portfolio. This includes a wide range of generic APIs such as Naproxen, Gabapentin, and Dextromethorphan. It also includes Valsartan, Levetiracetam, Phenylephrine, and Pregabalin. The company also produces nutraceutical ingredients like Lutein, beta-carotene, and Lycopene. It also produces Astaxanthin, Vitamin A1, and Vitamin D3.
Divis Laboratories Ltd. has established itself as a leading manufacturer of generic APIs globally. It has a significant market share in products like Naproxen, Dextromethorphan, and Gabapentin. The company’s API production is backward integrated. This ensures a reliable supply chain and cost efficiency. Divis Laboratories also offers custom synthesis services. They provide contract development and manufacturing (CDMO) offers. It also offers contract research manufacturing services (CRAMS) for some of the world’s largest pharmaceutical companies.
The company is committed to quality, innovation, and sustainability. This has earned it many awards and recognitions from various regulatory and statutory bodies. Divis Laboratories has been honoured for its manufacturing, environment, health, and safety excellence. Today, Divis Laboratories Ltd. continues to be led by its founder, Dr Murali K. Divi, and the full-time director, Mr Kiran S. Divi. The promoters hold a large shareholding, reflecting their strong obligation to the company’s growth and success.
With many decades of experience, Divis Laboratories Ltd. remains dedicated and continue to deliver high-quality pharmaceutical products to meet global healthcare needs. The company has large-scale manufacturing capabilities. It adheres to global regulatory standards and focuses on innovation. These features position it as a significant player in the pharmaceutical industry.
The company is renowned for its extensive range of products. This includes generic APIs such as Naproxen and Dextromethorphan. It also includes Gabapentin, Pregabalin, and Valsartan. The product list also includes Levetiracetam and Phenylephrine. Additionally, Divis Laboratories produces nutraceutical ingredients like beta-carotene and Lutein. It also produces Astaxanthin and Lycopene. The company also produces Vitamin D3 and Vitamin A. These products highlight the company’s duty to quality and innovation.
Divis Laboratories Ltd. is led by its founder and Managing Director, Dr Murali K. Divi, and the Whole-time Director, Mr Kiran S. Divi. The promoters hold a significant shareholding of approximately 51.90%. This reflects their strong commitment to the company’s growth and success.
Here are the top managing promoters of the company:
-
Ramesh B V Nimmagadda
-
Murali K Divi
-
Kiran S Divi
-
Nilima Prasad Divi
-
S Devendra Rao
The registered office of Divis Laboratories Ltd. is located at 10 & 13 - A, S V Road, Mumbai, Maharashtra 400102. The company’s management team continues to drive its vision. They deliver high-quality pharmaceutical products to meet global healthcare needs.
The company is one of the leading manufacturers of generic APIs globally. Divis Laboratories Ltd. has established itself as a major player in the pharmaceutical industry. It has large-scale manufacturing capabilities. It also adheres to global regulatory standards, which have earned it a reputable position in the market.
History of the Company
Dr. Murali K. Divi founded Divis Laboratories Ltd. It has grown to become a significant player in the global pharmaceutical industry. It was initially established as Divis Research Central. The company focused on developing commercial processes. This was for manufacturing Active Pharmaceutical Ingredients (APIs) and intermediates. In 1994, the company rebranded to Divis Laboratories Ltd. This signalled its intent to enter the API and intermediates manufacturing industry.The company’s first manufacturing facility was set up in 1995 at Choutuppal, Telangana. This facility marked the beginning of Divis’ journey in large-scale manufacturing. The company received ISO-9002 certification from SGS-Yarsley of the UK in 1997. This certification highlights its commitment to quality standards. By 1999, Divis Laboratories had earned a Certificate of Suitability (CoS) from the European Directorate. This certification was for the quality of its Naproxen production.
In 2002, Divis Laboratories expanded its manufacturing capabilities. They established a second facility at Chippada near Visakhapatnam. This expansion was crucial for meeting the growing global demand for APIs and intermediates. The company went public with its initial public offering (IPO) on February 17, 2003. The IPO further solidified its financial foundation and enabled future growth.
Significant milestones marked the early 2000s for Divis Laboratories. The company received multiple certifications, including ISO-14001, from SGS International AG of Switzerland. It also received OHSAS-18001 from BVQI of London. These reflect its adherence to international standards in quality and occupational health and safety. The US FDA also inspected and approved the company’s facilities. This approval underlines its compliance with stringent regulatory requirements.
In 2010, Divis Laboratories Ltd. established a research centre in Hyderabad. It was to focus on fundamental research in niche business segments. This move aimed to enhance the company’s R&D capabilities and foster innovation. Over the years, Divis Laboratories has continued to expand its product portfolio. This includes a wide range of generic APIs such as Naproxen, Gabapentin, and Dextromethorphan. It also includes Valsartan, Levetiracetam, Phenylephrine, and Pregabalin. The company also produces nutraceutical ingredients like Lutein, beta-carotene, and Lycopene. It also produces Astaxanthin, Vitamin A1, and Vitamin D3.
Divis Laboratories Ltd. has established itself as a leading manufacturer of generic APIs globally. It has a significant market share in products like Naproxen, Dextromethorphan, and Gabapentin. The company’s API production is backward integrated. This ensures a reliable supply chain and cost efficiency. Divis Laboratories also offers custom synthesis services. They provide contract development and manufacturing (CDMO) offers. It also offers contract research manufacturing services (CRAMS) for some of the world’s largest pharmaceutical companies.
The company is committed to quality, innovation, and sustainability. This has earned it many awards and recognitions from various regulatory and statutory bodies. Divis Laboratories has been honoured for its manufacturing, environment, health, and safety excellence. Today, Divis Laboratories Ltd. continues to be led by its founder, Dr Murali K. Divi, and the full-time director, Mr Kiran S. Divi. The promoters hold a large shareholding, reflecting their strong obligation to the company’s growth and success.
With many decades of experience, Divis Laboratories Ltd. remains dedicated and continue to deliver high-quality pharmaceutical products to meet global healthcare needs. The company has large-scale manufacturing capabilities. It adheres to global regulatory standards and focuses on innovation. These features position it as a significant player in the pharmaceutical industry.
Know More
